Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis

[1]  S. Holly,et al.  Bioactive Ether Lipids: Primordial Modulators of Cellular Signaling , 2021, Metabolites.

[2]  P. Gregersen,et al.  Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti–Citrullinated Protein Antibody–Positive Population , 2020, Arthritis & rheumatology.

[3]  O. Quehenberger,et al.  Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis , 2020, Arthritis & rheumatology.

[4]  G. Roda,et al.  Functional Lipids in Autoimmune Inflammatory Diseases , 2020, International journal of molecular sciences.

[5]  E. Karlson,et al.  Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study. , 2020, Rheumatology.

[6]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[7]  Nguyen Phuoc Long,et al.  Comprehensive Multi-Omics Analysis Reveals Aberrant Metabolism of Epstein–Barr-Virus-Associated Gastric Carcinoma , 2019, Cells.

[8]  P. Larsen,et al.  Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score , 2019, RMD Open.

[9]  K. Glunde,et al.  Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer , 2019, NMR in biomedicine.

[10]  F. Parveen,et al.  An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases , 2019, International journal of molecular sciences.

[11]  O. Fiehn,et al.  Systematic Error Removal Using Random Forest for Normalizing Large-Scale Untargeted Lipidomics Data. , 2019, Analytical chemistry.

[12]  J. Brouwers,et al.  LION/web: a web-based ontology enrichment tool for lipidomic data analysis , 2018, bioRxiv.

[13]  Valerio Chiurchiù,et al.  Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..

[14]  A. Iagnocco,et al.  Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce—Part 1: definition and development of a standardised, consensus-based scoring system , 2017, RMD Open.

[15]  I. Lodhi,et al.  Structural and functional roles of ether lipids , 2017, Protein & Cell.

[16]  G. Di Sante,et al.  Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? , 2017, Annals of the rheumatic diseases.

[17]  Xianlin Han,et al.  Lipidomics for studying metabolism , 2016, Nature Reviews Endocrinology.

[18]  M. Maccarrone,et al.  Bioactive lipids as modulators of immunity, inflammation and emotions. , 2016, Current opinion in pharmacology.

[19]  P. Emery,et al.  Review: Preclinical Rheumatoid Arthritis: Progress Toward Prevention , 2016, Arthritis & rheumatology.

[20]  P. Gregersen,et al.  Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. , 2016, Rheumatology.

[21]  F. Wagner.  GO-PCA: An Unsupervised Method to Explore Gene Expression Data Using Prior Knowledge , 2015, PloS one.

[22]  J. Castillo-Ortiz,et al.  Autoantibodies in Prediction of the Development of Rheumatoid Arthritis Among Healthy Relatives of Patients With the Disease , 2015, Arthritis & rheumatology.

[23]  M. Dougados,et al.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update , 2015 .

[24]  S. Ajeganova,et al.  Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms , 2015, Annals of the rheumatic diseases.

[25]  Masanori Arita,et al.  MS-DIAL: Data Independent MS/MS Deconvolution for Comprehensive Metabolome Analysis , 2015, Nature Methods.

[26]  G. Firestein,et al.  Choline kinase inhibition in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[27]  T. Pincus,et al.  Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. , 2014, Clinical and experimental rheumatology.

[28]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[29]  P. Jakobsson,et al.  Persisting eicosanoid pathways in rheumatic diseases , 2014, Nature Reviews Rheumatology.

[30]  J. Kremer,et al.  Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year , 2014 .

[31]  N. Vaziri,et al.  Lysophosphatidylcholine, Oxidized Low-Density Lipoprotein and Cardiovascular Disease in Korean Hemodialysis Patients: Analysis at 5 Years of Follow-up , 2013, Journal of Korean medical science.

[32]  Debashis Paul,et al.  A Regularized Hotelling’s T2 Test for Pathway Analysis in Proteomic Studies , 2011, Journal of the American Statistical Association.

[33]  T. Therneau,et al.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease , 2011, Annals of the rheumatic diseases.

[34]  M. Dougados,et al.  Extended report: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search , 2010 .

[35]  Nguyen Dang Hung,et al.  Lysophosphatidylcholine Containing Docosahexaenoic Acid at the sn-1 Position is Anti-inflammatory , 2010, Lipids.

[36]  T. Pincus,et al.  Erythrocyte Sedimentation Rate, C-Reactive Protein, or Rheumatoid Factor Are Normal at Presentation in 35%–45% of Patients with Rheumatoid Arthritis Seen Between 1980 and 2004: Analyses from Finland and the United States , 2009, The Journal of Rheumatology.

[37]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[38]  Mohsen Sadatsafavi,et al.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.

[39]  G. Schmitz,et al.  Mass spectrometric analysis of lipid species of human circulating blood cells. , 2008, Biochimica et biophysica acta.

[40]  A. Shevchenko,et al.  Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. , 2008, Journal of lipid research.

[41]  R. Schneiter,et al.  Lipid signalling in disease , 2008, Nature Reviews Molecular Cell Biology.

[42]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[43]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[44]  Xianlin Han,et al.  Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. , 2003, Journal of lipid research.

[45]  Marcin Szkudlarek,et al.  Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[46]  F. Wolfe,et al.  The clinical and research significance of the erythrocyte sedimentation rate. , 1994, The Journal of rheumatology.

[47]  A. Bennett,et al.  Factors regulating the secretion of lysophosphatidylcholine by rat hepatocytes compared with the synthesis and secretion of phosphatidylcholine and triacylglycerol. Effects of albumin, cycloheximide, verapamil, EGTA and chlorpromazine. , 1988, The Biochemical journal.

[48]  藤井隆夫.  Treating rheumatoid arthritis to the target―関節リウマチの治療戦略をここまで変えたものは何か― , 2016 .

[49]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[50]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[51]  A. Drosos,et al.  Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2 , 2007, Arthritis research & therapy.

[52]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[53]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.